Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

[1]  J. Byrne,et al.  De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. , 2019, The Lancet. Haematology.

[2]  J. Cortes,et al.  Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors , 2018, American journal of hematology.

[3]  I. Glauche,et al.  Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data , 2018, Haematologica.

[4]  Martin C. Müller,et al.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. , 2018, The Lancet. Oncology.

[5]  J. Byrne,et al.  De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. , 2017, The Lancet. Haematology.

[6]  Paul W Dickman,et al.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Richter,et al.  The concept of treatment-free remission in chronic myeloid leukemia , 2016, Leukemia.

[8]  H. Kantarjian,et al.  CME Information: Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring , 2016 .

[9]  J. Apperley.  Chronic myeloid leukaemia , 2015, The Lancet.

[10]  J. Cayuela,et al.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Colomer,et al.  Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response , 2016, Annals of Hematology.